Orbus Pharma Inc.
TSX : ORB

Orbus Pharma Inc.

July 25, 2005 16:05 ET

Orbus Signs Cefuroxime Axetil Licensing Agreement

TORONTO, ONTARIO--(CCNMatthews - July 25, 2005) - Orbus Pharma Inc. (TSX:ORB) ("Orbus") today announced the signing of a license agreement with Teva Generics Belgium ("TEVA") (www.tevabelgium.be).

Under terms of the license agreement, TEVA will distribute the product in Belgium and Luxembourg and pay Orbus a license fee. Orbus will manufacture the product in its Cambridge plant and supply TEVA with packaged product. Orbus is awaiting regulatory approval in Europe and marketing is expected to begin in the first quarter of 2006.

Cefuroxime axetil is an antibiotic used to treat certain infections such as bronchitis, infections of the ears, throat, sinuses, urinary tract and skin. Retail annual sales in Belgium are approximately 13 million Euros.

Orbus, headquartered in Markham, Ontario, pursues a strategy of generating revenue through the manufacture of off-patent pharmaceuticals, capitalizing on its ability to support the development and commercialization of a range of products at affordable costs.

Contact Information

  • Orbus Pharma Inc.
    Jeffrey W. Renwick
    President & CEO
    (905) 943-9444 ext. 227